Considerations for the use of botulinum toxin in pain management.
Lang
Amy M
AM
Atlanta Orthopedics, and Emory University Department of Rehabilitation Medicine, GA, USA. alang1@bellsouth.net
D000698:Analgesia / Q000379:methods; D018726:Anti-Dyskinesia Agents / Q000627:therapeutic use*; D001905:Botulinum Toxins / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003937:Diagnosis, Differential; D017277:Drug Approval; D006801:Humans; D009209:Myofascial Pain Syndromes / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D010147:Pain Measurement; D018579:Patient Selection; D015995:Prevalence; D014103:Torticollis / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
D018726:Anti-Dyskinesia Agents; D001905:Botulinum Toxins